KR101467453B1 - 에프지에프２ 결합 펩타이드 및 그의 용도 - Google Patents

에프지에프２ 결합 펩타이드 및 그의 용도 Download PDF

Info

Publication number
KR101467453B1
KR101467453B1 KR1020087020664A KR20087020664A KR101467453B1 KR 101467453 B1 KR101467453 B1 KR 101467453B1 KR 1020087020664 A KR1020087020664 A KR 1020087020664A KR 20087020664 A KR20087020664 A KR 20087020664A KR 101467453 B1 KR101467453 B1 KR 101467453B1
Authority
KR
South Korea
Prior art keywords
ptx3
fgf2
seq
peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087020664A
Other languages
English (en)
Korean (ko)
Other versions
KR20080096794A (ko
Inventor
마르코 프레스타
마우라 카모치
마르코 루스나티
마우리지오 콜롬보
도메니코 마스트로이아니
Original Assignee
씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이. filed Critical 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이.
Publication of KR20080096794A publication Critical patent/KR20080096794A/ko
Application granted granted Critical
Publication of KR101467453B1 publication Critical patent/KR101467453B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
KR1020087020664A 2006-01-24 2008-08-22 에프지에프２ 결합 펩타이드 및 그의 용도 Expired - Fee Related KR101467453B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06001457.8 2006-01-24
EP06001457 2006-01-24

Publications (2)

Publication Number Publication Date
KR20080096794A KR20080096794A (ko) 2008-11-03
KR101467453B1 true KR101467453B1 (ko) 2014-12-01

Family

ID=37421191

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087020664A Expired - Fee Related KR101467453B1 (ko) 2006-01-24 2008-08-22 에프지에프２ 결합 펩타이드 및 그의 용도

Country Status (19)

Country Link
US (1) US8076300B2 (enExample)
EP (1) EP1973944B1 (enExample)
JP (1) JP5427415B2 (enExample)
KR (1) KR101467453B1 (enExample)
CN (1) CN101384622B (enExample)
AU (1) AU2007209581B2 (enExample)
BR (1) BRPI0707239A8 (enExample)
CA (1) CA2637295C (enExample)
DK (1) DK1973944T3 (enExample)
EA (1) EA015339B1 (enExample)
ES (1) ES2575517T3 (enExample)
HR (1) HRP20160600T1 (enExample)
HU (1) HUE029212T2 (enExample)
IL (1) IL192800A (enExample)
MX (1) MX2008009289A (enExample)
PL (1) PL1973944T3 (enExample)
PT (1) PT1973944T (enExample)
SI (1) SI1973944T1 (enExample)
WO (1) WO2007085412A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204928A1 (en) * 2017-05-05 2018-11-08 Board Of Regents, The University Of Texas System Fgl2 monoclonal antibodies and their use in treating malignant tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blood Vol.104:92-99 (온라인 출판일 2004. 03. 18.) *
Blood Vol.104:92-99 (온라인 출판일 2004. 03. 18.)*
Blood Vol.91:3289-3299 (1998. 05. 01.) *

Also Published As

Publication number Publication date
MX2008009289A (es) 2008-10-17
HRP20160600T1 (hr) 2016-07-01
CA2637295A1 (en) 2007-08-02
AU2007209581B2 (en) 2013-03-28
CN101384622B (zh) 2013-03-27
DK1973944T3 (en) 2016-06-27
SI1973944T1 (sl) 2016-07-29
BRPI0707239A8 (pt) 2018-01-30
ES2575517T3 (es) 2016-06-29
KR20080096794A (ko) 2008-11-03
IL192800A0 (en) 2009-02-11
WO2007085412B1 (en) 2007-10-11
JP2009523457A (ja) 2009-06-25
IL192800A (en) 2015-04-30
EA015339B1 (ru) 2011-06-30
BRPI0707239A2 (pt) 2011-04-26
HUE029212T2 (en) 2017-02-28
CN101384622A (zh) 2009-03-11
EP1973944A1 (en) 2008-10-01
PL1973944T3 (pl) 2016-09-30
PT1973944T (pt) 2016-07-07
EA200870188A1 (ru) 2009-02-27
US20090215689A1 (en) 2009-08-27
EP1973944B1 (en) 2016-05-11
WO2007085412A1 (en) 2007-08-02
CA2637295C (en) 2017-06-13
AU2007209581A1 (en) 2007-08-02
US8076300B2 (en) 2011-12-13
JP5427415B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
JP2020178689A (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
KR100682666B1 (ko) 항혈관형성 단백질 및 이들을 사용하는 방법
JP5091679B2 (ja) マルチドメイン両親媒性ヘリックスペプチドおよびその使用方法
CZ302303B6 (cs) Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor
US8658768B2 (en) Method for enhancing phagocytosis of phosphatidylserine-exposing cells
WO2013149094A1 (en) TGFβ TYPE II-TYPE III RECEPTOR FUSIONS
US6225285B1 (en) Semaphorin K1
JP2000502569A (ja) Ｏｂタンパク質レセプター及び関連組成物と関連方法
JP5416901B2 (ja) 興味のある分子の細胞内位置決めのためのベクターとして用いられるマウロカルシン由来ペプチド
US8722623B2 (en) Compositions and methods utilizing fibrin beta chain fragments
KR20030074796A (ko) 혈소판 당단백질 ｉｂ 알파 융합 폴리펩티드 및 이의 사용방법
KR101467453B1 (ko) 에프지에프２ 결합 펩타이드 및 그의 용도
AU2011200901A1 (en) Methods and Agents for the Treatment of Cancer
JP2008013436A (ja) 血管形成促進剤
KR100641535B1 (ko) 브이이지에프 펩티드 및 그 용도
Rebollo et al. Peptides that inhibit binding between set and caspase-9
JP2005073528A (ja) 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
WO2008077938A1 (en) Modulators of talin/integrin association and use thereof
JP2006500906A (ja) 抗血管新生活性を有する有機化合物群
CA2779353A1 (en) Acceleration of wound healing by a tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi)-anchors
US20030216547A1 (en) Cerebellin homologous polypeptides and therapeutic uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20171109

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181126

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181126